Published in

Toulouse, France; Europa Digital && Publishing; [2014], Eurointervention, 3(7), p. 323-331

DOI: 10.4244/eijv7i3a56

Links

Tools

Export citation

Search in Google Scholar

Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial

Journal article published in 2011 by Lisette Okkels Jensen, Michael Mæng, Per Thayssen, Anton Villadsen, Anton Boel Villadsen, Lars Romer Krusell, Hans Erik Botker ORCID, Knud Erik Pedersen, Jens Aaroe, Evald Høj Christiansen, Thomas Vesterlund, Knud Hansen, Knud Noerregaard Hansen, Jan Ravkilde, Hans-Henrik Tilsted Hansen and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Patients with diabetes mellitus have increased risk of in-stent restenosis after coronary stent implantation due to neointimal hyperplasia (NIH). The aim of this study was to use quantitative coronary angiography (QCA) and volumetric intravascular ultrasound (IVUS) to evaluate the effects of the sirolimus-eluting Cypher® stent (SES) and the zotarolimus-eluting Endeavor® stent (ZES) on angiographic late lumen loss and intima hyperplasia in diabetic patients.